BiotechTube
RevolKa

RevolKa

Sendai, Japan· Est.

RevolKa uses AI-driven protein engineering to accelerate the development of novel biopharmaceuticals and industrial enzymes.

revolka.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Estimated funding: $710M

AI Company Overview

RevolKa uses AI-driven protein engineering to accelerate the development of novel biopharmaceuticals and industrial enzymes.

Rare Diseases

Technology Platform

aiProtein® is a proprietary protein engineering platform that integrates artificial intelligence (using custom models and Low-N learning) with laboratory-based directed evolution to design high-performance proteins from limited experimental data.

Opportunities

Significant opportunity to leverage its validated AI-protein platform for broad partnership deals in antibody and enzyme engineering, and to advance its proprietary rare disease therapeutics with government grant support.

Risk Factors

As a young, platform-focused company, RevolKa faces risks including dependence on key partnerships for revenue, technological competition from global AI-biotech firms, and the inherent challenges of translating platform success into proprietary clinical assets.

Competitive Landscape

Competes with global AI-driven protein design companies like Absci, Generate Biomedicines, and LabGenius. RevolKa differentiates through its specific hybrid AI/wet-lab evolution approach, strong academic roots from Tohoku University, and early validation with major Japanese pharma partners.

More companies in Japan →